RMA
ALDX icon

Roffman Miller Associates’s Aldeyra Therapeutics ALDX Stock Holding History

Roffman Miller Associates’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-500
Closed -$4.2K – 85
2023
Q2 		$4.2K Buy
+500
New +$4.93K ﹤0.01% 126

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Roffman Miller Associates's ALDX Position: Q3 2023 in Review

Roffman Miller Associates sold out of Aldeyra Therapeutics (ALDX) in Q3 2023, closing a stake of 500 shares — an estimated $4.2K sold.

Roffman Miller Associates first reported a position in ALDX in Q2 2023 and held it in 1 quarter. The position peaked at $4.2K in Q2 2023. 120 funds tracked by Wall St. Rank hold ALDX as of Q3 2023.

  • Roffman Miller Associates reported no remaining Aldeyra Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Roffman Miller Associates sold 500 Aldeyra Therapeutics shares in Q3 2023, an estimated $4.2K.
  • Roffman Miller Associates first reported a position in Aldeyra Therapeutics in Q2 2023 and held it in 1 quarter.
  • Roffman Miller Associates's Aldeyra Therapeutics position peaked at $4.2K in Q2 2023.
  • 120 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2023.

Based on Roffman Miller Associates's 13F filing for Q3 2023, filed 9 Nov 2023.